deaths (OS)

la/mBC - HER2 positive - 2nd Line (L2) breast cancer - HER2-positive la/mBC - HER2 positive la/mBC - HER2 positive - 2nd Line (L2)

versus trastuzumab plus vinorelbine
afatinib plus vinorelbine vs. trastuzumab plus vinorelbine 1 1.48 [1.12; 1.95], 1 RCT, I2=0%
statistically significant harm